News

GlobalData on MSN16h
BioVersys and Shionogi agree to develop ansamycin leads
BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin ...
pharmaphorum1d
Shionogi puts up to $600m behind BioVersys antibiotics
Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...
Fierce Biotech2d
Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program
Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. | Storied Japanese pharma ...
The Pharma Letter1d
BioVersys joins forces with Shionogi on ansamycin development
Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese ...
Pharmabiz1d
BioVersys & Shionogi ink global research collaboration for broad-spectrum NTM clinical candidate
BioVersys & Shionogi ink global research collaboration for broad-spectrum NTM clinical candidate: Basel, Switzerland Thursday, July 3, 2025, 10:00 Hrs [IST] BioVersys AG, a multi- ...
CIDRAP1d
Partnership aims to foster development of drug for non-TB mycobacteria
Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.
BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, July 02, 2025 (GLOBE NEWSWIRE) -- The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to ...